Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - Jorgensen, K K; Olsen, I C; Goll, G L (Lancet, 2017)
et al.